Revenue growth for the Indian pharmaceutical industry is expected to remain healthy at 13-15% in FY2027 aided by broad-based growth across all key geographies, except the US, and incremental revenues from acquisitions. The credit profile of Indian pharmaceutical companies is expected to remain healthy despite debt-funded acquisitions.

Exhibit: Trend in revenues and OPM*